CDDO-EA Attenuates Acute Seizures and Suppresses Post-Status Epilepticus Epileptogenesis
Open Access
- 7 October 2026
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 15 (10) , 1296
Abstract
We aimed to investigate the acute anticonvulsant and long-term antiepileptogenic effects of the synthetic triterpenoid CDDO-EA in complementary experimental models of epilepsy. CDDO-EA was evaluated in the pentylenetetrazol seizure model and a kainic acid-induced post-status epilepticus model. Acute seizure severity, latency to generalized seizures, oxidative stress and inflammatory markers, spontaneous recurrent seizures, and hippocampal neuronal survival were assessed. In the pentylenetetrazol model, CDDO-EA pretreatment reduced maximal seizure severity and prolonged the latency to stage V-VI seizures. These effects were associated with decreased inflammatory cytokine levels and malondialdehyde levels, alongside increased superoxide dismutase and catalase activities 24 h after pentylenetetrazol administration. In the post-status epilepticus model, two weeks of CDDO-EA treatment significantly delayed the onset of spontaneous recurrent seizures and produced sustained reductions in weekly seizure frequency and cumulative seizure burden. Histological analysis demonstrated greater neuronal preservation in the hippocampal CA1 and CA3 regions of CDDO-EA-treated animals compared with vehicle controls. CDDO-EA exerts both anticonvulsant and disease-modifying effects by attenuating seizure severity, restoring redox-inflammatory homeostasis, preserving hippocampal neurons, and suppressing epileptogenesis after status epilepticus, supporting its therapeutic potential as a novel strategy for epilepsy.Keywords
Funding Information
- Israel Science Foundation (1976/20)
- Ministry of Innovation, Science and Technology (5100)
This publication has 66 references indexed in Scilit:
- Targeting Hsp90 with cemdomespib reduces seizure burden and alters disease course in preclinical epilepsy modelsEpilepsia, 2026
- Enigmatic intractable Epilepsy patients have antibodies that bind glutamate receptor peptides, kill neurons, damage the brain, and cause Generalized Tonic Clonic SeizuresJournal of Neural Transmission, 2025
- Activation of nicotinamide adenine dinucleotide phosphate oxidase is the primary trigger of epileptic seizures in rodent modelsAnnals of Neurology, 2019
- Losartan prevents acquired epilepsy via TGF‐β signaling suppressionAnnals of Neurology, 2014
- Post-Seizure α-Tocopherol Treatment Decreases Neuroinflammation and Neuronal Degeneration Induced by Status Epilepticus in Rat HippocampusMolecular Neurobiology, 2014
- Nrf2 defense pathway: Experimental evidence for its protective role in epilepsyAnnals of Neurology, 2013
- Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosisFree Radical Biology and Medicine, 2011
- Tumor necrosis factor‐α inhibits seizures in mice via p75 receptorsAnnals of Neurology, 2005
- Mitochondrial dysfunction and oxidative stress: cause and consequence of epileptic seizuresFree Radical Biology and Medicine, 2004
- Modification of seizure activity by electrical stimulation: II. Motor seizureElectroencephalography and Clinical Neurophysiology, 1972